Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC006833 | Panoply™ Human HAPLN1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC006833 | Panoply™ Human HAPLN1 Over-expressing Stable Cell Line | Inquiry |
| CLOE-1532 | Human HAPLN1 HEK293 Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD07325Z | Human HAPLN1 adenoviral particles | Inquiry |
| LV14386L | human HAPLN1 (NM_001884) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH113933 | shRNA set against Mouse Hapln1(NM_013500.4) | Inquiry |
| SHH113937 | shRNA set against Rat Hapln1(NM_019189.2) | Inquiry |
| SHH310289 | shRNA set against Human HAPLN1 (NM_001884.3) | Inquiry |
| SHH310293 | shRNA set against Mouse HAPLN1 (NM_013500.4) | Inquiry |
| SHH310297 | shRNA set against Rat HAPLN1 (NM_019189.2) | Inquiry |
| SHW005974 | shRNA set against Chicken HAPLN1 (NM_205482) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFR011487 | Rat Hapln1 cDNA Clone(NM_019189.2) | Inquiry |
| MiUTR1M-05538 | HAPLN1 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-02379 | HAPLN1 miRNA 3'UTR clone | Inquiry |
| MiUTR4H-TG11399 | HAPLN1 miRNA 3'UTR clone | Inquiry |
| CDCB167449 | Chicken HAPLN1 ORF Clone (NM_205482) | Inquiry |
| CDCB184401 | Rabbit HAPLN1 ORF clone (XM_008261911.1) | Inquiry |
| CDCL151092 | Mouse Hapln1 ORF clone (NM_013500.4) | Inquiry |
| CDCL184546 | Human HAPLN1 ORF clone(NM_001884.3) | Inquiry |
| CDCR378520 | Rat Hapln1 ORF Clone(NM_019189.2) | Inquiry |
| CDCS410495 | Human HAPLN1 ORF Clone (BC057808) | Inquiry |
Recent Research Progress
HAPLN1, Hyaluronan And Proteoglycan Link Protein 1, is an acid glycoprotein with 354-amino. It belongs the link protein gene family which consists of four HAPLN members. Similar to the other three link proteins, structure of HAPLN1 has NH2-terminal signal sequence followed by immunoglobulin-like domain and two link modules or proteoglycan tandem repeats. Interestingly, proteoglycan tandem repeats mentioned above, or link modules, is the main site for mediating binding to hyaluronic acid (HA). All structures of HAPLN1 above indicate that it has some pathological activity in some field as the recent studies.
Some researches proved that serving as a major component of cartilage extracellular matrix (ECM), HAPLN1 stabilizes aggregates of aggrecan and HA. In the absence of HAPLN1, aggregates are smaller and less stable. HAPLN1 binds to aggrecan on the HA chain in a 1:1 ratio. The obtained aggregates are captured within the mesh-like network of type II collagen fibrils producing a large stable macromolecular structures, which contributes to resist compression and shock absorption in the joint. Although HAPLN1 is a major component of cartilage ECM, it is also highly expressed in noncartilaginous tissues such as small intestine and placenta, embryonic and adult heart tissues, and, to a lower extent, many other tissues.
HAPLN1 and tumorigenesis
Some progress of expression of HAPLN1 in cancers and its significance for tumorigenesis has been made. Sihem Mebarki et al. showed that there are two tight gene networks associating cell surface Wnt signaling, stem/progenitor markers and mesenchymal commitment in hepatocellular carcinomas (HCCs). Both networks were linked by Hyaluronan And Proteoglycan Link Protein 1 (HAPLN1), which appeared de novo in aggressive HCCs expressing cytoplasmic β-catenin and stem cell markers. HAPLN1 was independently associated with bad overall and disease-free outcome. So they has come to a conclusion that HAPLN1 reflects a signaling network leading to stemness, mesenchymal commitment and hepatocellular carcinomas progression. ZENGZENG WANG et al. indicated that HAPLN1 may be involved in the pathogenesis of clear cell renal cell carcinoma as HAPLN1 was lowly expressed and highly methylated in clear cell renal cell carcinoma tissues. Interestingly, a related research has showed that HAPLN1 is a novel pathogenic factor in multiple myeloma (MM) that induces the activation of an atypical NF-κB, a family of transcription factors that play a key role in cell survival and proliferation in MM, and thereby promotes the resistance of bortezomib which is a proteasome inhibitor used in the management of MM, inhibiting both canonical and noncanonical activation of NF-κB in MM cells.
HAPLN1 and other diseases
According to rencent researches, HAPLN1 also has an impact on other diseases. As some research reported, by upregulating HAPLN1 and downregulating Versican at the terminal stage, human bone marrow mesenchymal stromal cells (MSCs) can ameliorate progression of amyotrophic lateral sclerosis (ALS) which is a progressive neurodegenerative disorder resulting in a lethal outcome, significantly improve motor activity, and prolong survival. What’s more, there has been a research showed that as some extracellular matrix proteins including HAPLN1 are highly expressed in human cartilage and human articular chondrocytes, a low oxygen microenvironment may act to modulate cell proliferation and chondrogenic differentiation of both AMSCs and chondrocytes.
References: